CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and in…
$5.32+1.72%
报价 2026-11-06
市值
$414.7M
EV
$527.1M
PE (TTM)
3.4x
预期 PE (FY2026)
10.8x
52 周区间距高点 -58.2%
$5.23$12.73
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CRMDCorMedix Inc. | $414.7M | +1.7% | +3.7% | 82.8% | 3.4x | 2.4x | 2.5x | |
| TNGXTango Therapeutics, Inc. | $3.63B | +3.0% | -90.3% | 98.3% | – | – | – | |
| PVLAPalvella Therapeutics, Inc. | $2.53B | +12.2% | – | 0% | – | – | – | |
| SEPNSepterna, Inc. | $2.28B | +3.2% | +94.3% | 99.4% | – | – | 16.4x | |
| NBTXNanobiotix S.A. | $1.56B | +2.0% | – | 100% | – | – | – | |
| SVRASavara Inc. | $992.4M | +10.3% | +307.1% | 0% | – | – | – | |
| ABUSArbutus Biopharma Corporation | $724.1M | -0.4% | +1239.7% | 2.8% | – | – | – | |
| KURAKura Oncology, Inc. | $646.7M | +6.9% | +11.1% | 94.7% | – | – | – | |
| BCAXBicara Therapeutics Inc. Common Stock | $572.4M | +5.6% | – | 0% | – | – | – | |
| 同行中位数 | – | – | +94.3% | 48.8% | – | – | 16.4x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。